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SUMMARY – The components of metabolic syndrome lead to generalized atherosclerotic chang-
es and micro- and macrovascular complications with damage to systems and organs. Consequently, 
patients’ treatment with the resulting changes in the target organs is costly, complicated, and unpre-
dictable. We present a 65-year-old patient with diabetes diagnosed with hyperlipidemia, unregulated 
arterial hypertension in the presence of other metabolic syndrome components and who consequent-
ly developed complications of generalized atherosclerosis. Despite detailed, individually tailored ther-
apy, in line with current recommendations, we suggest that treatment success is very closely related 
and dependent on dietary measures, healthy living habits, and patient cooperation.
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study showed a significant effect of a 1 mmHg increase 
in blood pressure as a 26% increase in CVR. Resistant 
hypertension, which we define when blood pressure is 
not controlled despite optimum doses of 3 first-line 
classes of antihypertensive drugs, including thiazide 
diuretic, isolated, represents a significant factor of 
CVR4. Elevated uric acid levels are an independent 
risk factor for hypertension.5
The renin-angiotensin-aldosterone system (RAAS) 
is one of the key pathophysiological determinant of 
hypertension6,7,8. Its contribution is particularly im-
portant in conditions of reduced glomerular filtration 
rate (GFR) when, in addition to increased activity of 
angiotensin II levels, there is also directly stimulated 
basally increased sympathetic tone with no decrease 
during the night (non-dipping). Present diabetes, as 
well as uncontrolled proteinuria, contribute to the fur-
ther progression of kidney disease. We presented a pa-
tient with long-term unregulated arterial hypertension 
with other components of the metabolic syndrome 
and the consequent development of generalized ath-
erosclerosis complications.
Introduction
Metabolic syndrome (MS) is a significant and 
growing cause of mortality and morbidity in most 
countries’ general population, which is why cardiovas-
cular risk assessment (CVR) models1,2,3 have been de-
veloped. Metabolic syndrome is the medical term for a 
combination of diabetes, high blood pressure (hyper-
tension), and obesity (add ref.-www.nhs.uk). Hyper-
tension alone, and especially within MS, is one of the 
main risk factors for developing atherosclerosis. The 
goal of treatment is to achieve the maximum reduction 
in overall cardiovascular risk and mortality. In addition 
to all preventive and non-pharmacological measures 
that can be implemented and adequate treatment of 
diabetes and dyslipidemia, pharmacological blockade 
of the sympathetic nervous system with indirect re-
duction of catecholamine levels and modification of 
baroreceptor sensitivity is desirable. The ASCOT 
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Case Report
A 65-year-old patient, long-standing nicotinism, 
obese, diabetic for over 15 years without signs of dia-
betic retinopathy, suffers from hyperlipidemia, unregu-
lated arterial hypertension (for over 10 years), and gen-
eralized atherosclerosis. He was hospitalized for a 
planned kidney biopsy based on nephrotic proteinuria 
and azotemia. In physical examination: obesity (BMI 
33.4 kg/m²), pasty peripheral edema, thinned, pale 
skin of the lower extremities with hair loss, toenails on 
the remaining toes deformed. There was a significant 
difference in arterial pressure between the right 
(220/120 mmHg) and left arm (130/80 mmHg) with 
weakened distal arterial pulsations on lower extremi-
ties. He had an amputated toe on his left foot and the 
first three toes on his right foot. Subjectively, he com-
plained of pain in his legs with a significant reduction 
in the walking distance of 100-200 meters and erectile 
dysfunction. Laboratory findings: glucose 16.6 
mmol/L HbA1C 8.7% urea 19.9 mmol/L, creatinine 
172 µmol/L, creatinine clearance 37.1 ml/min, 24-
hour proteinuria 2.99 - 4.37 g/dU. Urine: proteins 
++/+++, cholesterol 6.0 mmol/L, HDL-K 1.39 
mmol/L, LDL - K 3.37 mmol/L, triglycerides 2.61 
mmol/L, urate 504 µmol/L. Ambulatory blood pres-
sure monitoring (ABPM) confirmed the absence of 
nocturnal drop (non-dipper). Before the hospitaliza-
tion, he was taking ACE inhibitor in low dose, thia-
zide diuretic, CCB low dose, BB, and short-acting in-
sulin 3 times a day. Aortic angiography describes se-
vere atheromatosis of the abdominal aorta, significant 
stenosis of the superior mesenteric artery, atheroscle-
rotic altered major branches of the renal arteries (no 
significant stenoses) with significantly stenosed acces-
sory renal arteries for the lower pole of both sides. 
From the L3 level, the infrarenal abdominal aorta was 
occluded, as was the iliac artery (AIC) bilaterally. Pres-
ent occlusion of the left subclavian artery and vertebral 
artery (VA) in a section 2 cm long and significant ste-
nosis of the ostium of the left vertebral artery. He had 
ischemic heart disease with a percutaneous coronary 
intervention (PCI) where coronary angiography re-
vealed significantly stenosed and calcified left anterior 
descending (LAD) coronary artery, which is resolved 
in two acts (due to hemodynamic instability of the pa-
tient) by implantation of a 2 stents-DES (“drug-elut-
ing stent”). According to cardiac ultrasound, he had 
mild concentric hypertrophy of the left ventricular 
wall, normal systolic function (EF about 60%) without 
clear regional outbursts of contractility. The left atrium 
was enlarged. The right ventricle was normal size, mild 
aortic valve atheromatosis with normal function. Col-
or Doppler indicates mitral regurgitation (MI) of the 
first degree and tricuspid insufficiency (TI) of the first 
degree without indirect indicators of pulmonary hy-
pertension. A kidney biopsy was performed. At the 
level of light and immunofluorescence microscopy in-
dicate diabetic nephropathy class III with advanced 
nephroangiosclerosis and perihilar sclerosis that prob-
ably refers to a secondary form of focal segmental glo-
merulosclerosis. The X-ray of the right foot showed 
osteolysis of the distal part of the distal phalanx of the 
third toe. Ekg showed sinus rhythm, frequency 70/
min, biphasic T wave in leads D1, aVL, and V5-V6. 
Figure 1. Severe abdominal aortic atheromatosis. T 
he main branches of the renal arteries are atherosclerotic 
changed, distal aorta is significantly stenosed as well as 
the proximal parts of the accessory renal arteries. 
Significant stenosis in the proximal part of the AMS. 
From the L3 level the infrarenal abdominal aorta is 
occluded as is the AIC bill. Left subclavian artery  
in the prevertebral part shows subocclusion  
and occlusion in a segment of 2 cm long; significant 
stenosis of the ostium of the left vertebral artery.
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We also investigated the possibility of OSA sy, but ac-
cording to his results on the Epworth scale (3) and 
heteroanamnesis, we discarded it.
Considering all his comorbidities, we prescribed 
ACE inhibitor in therapy in a higher dose than he had 
before, CCB in maximum dose, thiazide as a diuretic for 
a better metabolic profile, and a low dose of MRA-spi-
ronolactone, checking kidney function (eGFR) regularly.
Discussion
Long-term metabolic syndrome is a significant 
factor in cardiovascular risk with the presence of resis-
tant hypertension, high-grade renal failure, and ne-
phrotic proteinuria with its consequences (decreased 
GFR- 34-31 ml/min, nephrotic syndrome - 4.37 g/
dU, elevated cholesterol 6.0 mmol/L, LDL 3.61 
mmol/L, triglycerides 2.61 mmol/L and unregulated 
blood sugar -16.6mmol/L)1,2,4. Despite the modifica-
tion of antihypertensive therapy, ABPM still shows 
unregulated blood pressure. Initial endothelial damage 
at the level of the intima of the blood vessel, increased 
sympathetic activity, hyperglycemia, dyslipidemia, and 
many other proatherosclerotic factors lead to severe 
micro and macrovascular complications⁹. Peripheral 
occlusive artery disease (PAD) develops gradually and 
is clinically manifested with moderate to severe Ruth-
eford’s grade IIa/IIb claudication. Subjective distur-
bances are expressed as dull pain during physical work, 
long walks, standing, and exposure to cold. They usu-
ally disappear while resting, but they can also appear as 
pronounced cramps at night at rest, indicating the ex-
istence of neuropathy. Occasionally, ulcerations and 
gangrene are present on the peripheral parts of the 
lower extremities. Symptoms are usually reciprocal to 
the degree of morphological changes in the blood ves-
sels. This problem is significantly more common in 
males with diabetes, dyslipidemia, hypertension, in-
creased blood urate values, long-term smoking, and 
most of them also present coronary heart disease. Ath-
erosclerotic changes are generalized with severe steno-
ses of the aorta and many of its branches (Fig. 1). The 
consequences of these atherosclerotic changes are 
manifested in various organs and systems. In this case, 
it presents as ischemic heart disease with the need for 
PCI and valvular changes of MI, TI, chronic renal fail-
ure, cerebrovascular, and peripheral arterial occlusive 
disease. Given the complex interaction of the compo-
nents of metabolic syndrome and resistant hyperten-
sion as well as the high prevalence in the therapeutic 
approach, the emphasis, in addition to aggressive anti-
hypertensive, antidiabetic and hypolipemic therapy, 
should be on dietary measures and healthy lifestyle 
habits to prevent fatal consequences.
Conclusion
Given the complex interrelationship of all its co-
morbidities, male gender, and long-standing nicotinism, 
the question is which of these factors is the initial and 
causal driver of all consequences. Significant morpho-
logical changes require a multidisciplinary approach 
with the necessary changes in lifestyle habits: smoking 
cessation, weight loss, restriction of salt and fat intake, 
moderate exercise, regulation of blood sugar, urate, and 
blood pressure, and the necessary invasive interventions.
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Sažetak
GENERALIZIRANA ATEROSKLEROZA, METABOLIČKI SINDROM  
I REZISTENTNA HIPERTENZIJA – UZROCI I POSLJEDICE
D. Klarić, P. Grbić Pavlović i M. Klarić
Komponente metaboličkog sindroma dovode do generaliziranih aterosklerotskih promjena te mikro i makrovaskularnih 
komplikacija s oštećenjem sustava i organa. Slijedom toga, liječenje bolesnika s posljedicama promjena na ciljnim organima 
vrlo je skupo, složeno i nepredvidljivo. Predstavljamo 65-godišnjeg pacijenta, dijabetičara, kojem je dijagnosticirana hiper-
lipidemija, neregulirana arterijska hipertenzija u prisutnosti drugih komponenata metaboličkog sindroma i posljedično razvi-
jene komplikacije generalizirane ateroskleroze. Unatoč detaljnoj, individualno prilagođenoj terapiji, u skladu s trenutnim 
preporukama, smatramo da je uspjeh liječenja vrlo usko povezan i ovisi o prehrambenim mjerama, zdravim životnim navi-
kama i suradnji pacijenta.
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